What is the connection between ibrutinib and ibrutinib

Ibrutinib and ibrutinib (Ibrutinib) are actually the same drug, with exactly the same chemical name and mechanism of action. They are all BTK (Bruton's tyrosine kinase) inhibitors, targeted therapy drugs, mainly used to treat certain types of blood cancers, such as chronic lymphocytic leukemia (CLL/SLL), Waldenstrom's macroglobulinemia (WM) and mantle cell lymphoma (MCL) etc.

Ibrutinib was originally developed byImmunomedics, which was later acquired by Novartis and renamed ibrutinib. Therefore, when referring to "ibrutinib" or "ibrutinib", they actually refer to different names of the same drug, whose trade name is IMBRUVICA, or Yike (the trade name marketed in China). Clinically, a physician may choose to prescribe under one of these names based on licensing and market conditions. Regardless of its name, its function is to inhibit the growth and spread of cancer cells by blocking the BTK signaling pathway, thereby achieving therapeutic effects.

Ibrutinib can also help control the progression of these diseases and extend patient survival. This drug is usually taken by mouth in the form of capsules, tablets, etc. During the use of ibrutinib, doctors will regularly monitor the patient's blood indicators and condition changes to ensure the efficacy and safety of the drug. In terms of drug safety, ibrutinib has relatively few side effects, strong activity and high selectivity. Although some adverse reactions may occur during use, they are usually grade 1 or 2 and are relatively mild.

Therefore, ibrutinib and ibrutinib are the same medicine. Patients must strictly follow the doctor's instructions when taking the medicine and pay attention to their physical condition in order to respond to possible problems in a timely manner.